- South Korea
- /
- Chemicals
- /
- KOSE:A268280
Miwon Specialty Chemical (KRX:268280) Hasn't Managed To Accelerate Its Returns
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earned from that capital are also increasing. Ultimately, this demonstrates that it's a business that is reinvesting profits at increasing rates of return. So, when we ran our eye over Miwon Specialty Chemical's (KRX:268280) trend of ROCE, we liked what we saw.
Understanding Return On Capital Employed (ROCE)
For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. Analysts use this formula to calculate it for Miwon Specialty Chemical:
Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)
0.15 = ₩64b ÷ (₩536b - ₩100b) (Based on the trailing twelve months to March 2025).
Thus, Miwon Specialty Chemical has an ROCE of 15%. On its own, that's a standard return, however it's much better than the 7.3% generated by the Chemicals industry.
Check out our latest analysis for Miwon Specialty Chemical
Historical performance is a great place to start when researching a stock so above you can see the gauge for Miwon Specialty Chemical's ROCE against it's prior returns. If you want to delve into the historical earnings , check out these free graphs detailing revenue and cash flow performance of Miwon Specialty Chemical.
So How Is Miwon Specialty Chemical's ROCE Trending?
The trend of ROCE doesn't stand out much, but returns on a whole are decent. The company has employed 57% more capital in the last five years, and the returns on that capital have remained stable at 15%. Since 15% is a moderate ROCE though, it's good to see a business can continue to reinvest at these decent rates of return. Stable returns in this ballpark can be unexciting, but if they can be maintained over the long run, they often provide nice rewards to shareholders.
The Key Takeaway
In the end, Miwon Specialty Chemical has proven its ability to adequately reinvest capital at good rates of return. Therefore it's no surprise that shareholders have earned a respectable 93% return if they held over the last five years. So while investors seem to be recognizing these promising trends, we still believe the stock deserves further research.
Miwon Specialty Chemical does come with some risks though, we found 2 warning signs in our investment analysis, and 1 of those can't be ignored...
For those who like to invest in solid companies, check out this free list of companies with solid balance sheets and high returns on equity.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSE:A268280
Miwon Specialty Chemical
Engages in the manufacture and sales of energy-curing resins in Korea and internationally.
Excellent balance sheet and good value.
Similar Companies
Market Insights
Weekly Picks

Is this the AI replacing marketing professionals?
Pro Medicus: The Market Is Confusing a Lumpy Quarter With a Broken Business
The Rising Deal Risk That Helped Sink Netflix’s $72 Billion Bid for Warner Bros. Discovery
The Infrastructure AI Cannot Be Built Without
Recently Updated Narratives

Realty Income - A Fundamental and Historical Valuation
A Structured Counter‑Analysis of "The Leaking Dreadnought"

Alphabet Inc. (GOOG): The Gemini Era – Consolidating AI Dominance in 2026.
Popular Narratives

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share
Nu holdings will continue to disrupt the South American banking market

